Neurocrine Biosciences Inc (NBIX)

Nov 3, 2026

Neurocrine Biosciences (NBIX) experienced a significant intraday stock jump of over 15% after reporting strong Q3 2026 results. The rare disease drugmaker exceeded quarterly expectations and raised its guidance, with revenue reaching $1.1 billion, representing approximately 41% year-over-year growth. This performance marks the company's largest intraday gain in six years.

Nov 3, 2026

Neurocrine Biosciences is facing scrutiny over the safety of its Prader-Willi syndrome drug, Vykat, after another patient death brought the total reported deaths to eight. The company, which acquired the drug with Soleno Therapeutics in April, confirmed the latest death but reiterated confidence in Vykat's benefit-risk profile, attributing serious incidents to patients with complex medical issues. Neurocrine plans a new study in 2027 to explore dosing and safety for these vulnerable patients, aiming to restore confidence and growth for the drug.

Nov 3, 2026

Neurocrine Biosciences (NBIX) reported strong Q3 2026 earnings of $3.29 per share, significantly beating the Zacks Consensus Estimate of $2.54, and revenues of $1.12 billion, surpassing estimates by 8.12%. The company has consistently topped both EPS and revenue estimates over the past year, indicating robust financial performance. Despite outperforming expectations, NBIX shares have underperformed the S&P 500 year-to-date, prompting investor focus on future earnings outlook and management commentary.